文章：

葡萄膜黑色素瘤双特异性治疗综述

Review of bi-specific therapies in uveal melanoma 

原文发布日期：2022-03-02 

英文摘要：

Uveal melanoma is a rare subtype of melanoma that once metastatic portends a poor prognosis. Likely due to the distinct differences in biology, metastatic potential, and immunologic profile as compared to cutaneous melanoma, uveal melanoma’s response to immune checkpoint inhibition has been disappointing. Bi-specific fusion protein therapies (T cell engagers) are a novel strategy to forcibly bridge the immune system with a target on a cancer cell. This approach has been explored in a number of cancer types and has recently demonstrated success in uveal melanoma. Tebentafusp, a first in class ImmTAC (Immune-mobilizing monoclonal TCRs against cancer), has now shown an overall survival benefit when compared to investigator’s choice. This review aims to summarize the experience with this first in class bi-specific T cell engager as well as highlight bi-specifics as a novel treatment strategy in uveal melanoma. 

摘要翻译： 

葡萄膜黑色素瘤是黑色素瘤的一种罕见亚型，一旦发生转移则预后不良。由于其生物学特性、转移潜能和免疫学特征与皮肤黑色素瘤存在显著差异，葡萄膜黑色素瘤对免疫检查点抑制剂的反应一直不尽如人意。双特异性融合蛋白疗法（T细胞衔接器）是一种通过强制桥接免疫系统与癌细胞靶点的新型策略。该疗法已在多种癌症类型中得到探索，并近期在葡萄膜黑色素瘤治疗中取得突破。Tebentafusp作为全球首款ImmTAC（免疫动员性单克隆T细胞受体抗肿瘤药物），与研究者选择方案相比已展现出总生存期获益。本文旨在总结这款首创双特异性T细胞衔接器的临床应用经验，并重点探讨双特异性抗体作为葡萄膜黑色素瘤新型治疗策略的价值。

原文链接：

Review of bi-specific therapies in uveal melanoma